Please login to the form below

Not currently logged in


This page shows the latest RRMS news and features for those working in and with pharma, biotech and healthcare.

Novartis files for approval of MS drug in EU, US

Novartis files for approval of MS drug in EU, US

Around a quarter of patients with RRMS go onto develop SPMS within 10 years of their initial diagnosis. ... That’s the same mechanism as $3bn-a-year product Gilenya, which is approved to treat RRMS but didn’t hit the mark in SPMS trials.

Latest news

More from news
Approximately 8 fully matching, plus 31 partially matching documents found.

Latest from PMHub

  • It's time to change the conversation

    Take Multiple Sclerosis (MS) for example. MS has four different disease manifestations: Relapsing Remitting (RRMS), Secondary Progressive (SPMS), Primary Progressive (PPMS) and Progressive Relapsing (PRMS). ... Today however, given the research and the

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts


Add my company

Pegasus inspires healthy decisions through creative, inspirational and integrated communications. Working with ambitious clients, we deliver big ideas and far-reaching...

Latest intelligence

Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe’s leading hub for life sciences innovation...